Untangling the ErbB signalling network
2001 · Nature Reviews Molecular Cell Biology · 6,890 citations
https://doi.org/10.1038/35052073
M
Mark X. Sliwkowski
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
302
Papers
31.9K
Citations
61
h-index
102
i10-index
Mark X. Sliwkowski is an academic researcher from Molecular Oncology (United States). The author has contributed to research in topics: HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research & Lung Cancer Treatments and Mutations. The author has an h-index of 61, co-authored 257 publications.
Papers by this author
worksIdentification of Heregulin, a Specific Activator of p185 <sup>erbB2</sup>
1992 · Science · 963 citations
https://doi.org/10.1126/science.256.5060.1205
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
2009 · Cancer Cell · 825 citations
https://doi.org/10.1016/j.ccr.2009.03.020
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
1999 · Oncogene · 687 citations
https://doi.org/10.1038/sj.onc.1202526
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
1994 · Journal of Biological Chemistry · 643 citations
https://doi.org/10.1016/s0021-9258(17)36676-0
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
2010 · Journal of Clinical Oncology · 591 citations
https://doi.org/10.1200/jco.2009.26.2071
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat